Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

Trial Profile

A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs IONIS-HBV-LRx (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline; GlaxoSmithKline KK
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 28 Jan 2019 to 8 Nov 2019.
    • 08 Jan 2019 Planned primary completion date changed from 4 Nov 2018 to 31 Jan 2019.
    • 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top